Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.

Abstract:

:Available data indicate that the most common beta-lactamase produced by Branhamella catarrhalis is plasmid mediated. The same enzyme occurs in Moraxella nonliquefaciens, a commensal in the upper respiratory tract. The ability to produce the enzyme, which is known as BRO-1, can be transferred by conjugation from M. nonliquefaciens to B. catarrhalis. Since the first beta-lactamase-producing strains of B. catarrhalis appeared in 1977, the frequency of beta-lactamase production has increased rapidly; figures as high as 76% have been reported. The plasmid-mediated beta-lactamase TEM-1 occurs in several species of the genus Haemophilus. While the frequency of beta-lactamase production in H. influenzae is reported to be 10-15%, the incidence is significantly higher in non-pathogenic Haemophilus species. Both phenoxymethyl-penicillin and ampicillin promote the occurrence of beta-lactamase-producing strains, but the selective pressure exerted by ampicillin seems to be more pronounced. It may be possible to reduce the ecological effects of the penicillins by avoiding overdiagnosis of the most common bacterial infections of the respiratory tract, and by shortening the courses of antibiotic treatment.

journal_name

Drugs

journal_title

Drugs

authors

Eliasson I,Kamme C

doi

10.2165/00003495-198600313-00026

subject

Has Abstract

pub_date

1986-01-01 00:00:00

pages

116-21

eissn

0012-6667

issn

1179-1950

journal_volume

31 Suppl 3

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Pancreatic cancer: a review of emerging therapies.

    abstract::The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies, the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of panc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059050-00004

    authors: Rosenberg L

    更新日期:2000-05-01 00:00:00

  • Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

    abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565040-00003

    authors: Weinberger J

    更新日期:2005-01-01 00:00:00

  • MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

    abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0869-7

    authors: Shirley M,Taha MK

    更新日期:2018-02-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • [Clinical experience with nifedipine in the treatment of angina pectoris in Japan].

    abstract::Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666991-00003

    authors: Hosoda S

    更新日期:2006-01-01 00:00:00

  • Glipizide: a review of its pharmacological properties and therapeutic use.

    abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918050-00001

    authors: Brogden RN,Heel RC,Pakes GE,Speight TM,Avery GS

    更新日期:1979-11-01 00:00:00

  • Management of restless legs syndrome in patients on dialysis.

    abstract::Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. RLS occurs in 3-15% of the general population and in 10-30% of patients on maintenance dialysis. RLS may lea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666050-00003

    authors: Molnar MZ,Novak M,Mucsi I

    更新日期:2006-01-01 00:00:00

  • Heparin Therapy: regimens and management.

    abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197713010-00005

    authors: Deykin D

    更新日期:1977-01-01 00:00:00

  • What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

    abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00002

    authors: Momméja-Marin H,Carbon C

    更新日期:1999-06-01 00:00:00

  • Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

    abstract::There are many current concepts of the pathogenesis of rheumatic diseases which incorporate immunological, infectious and hereditary factors. Rheumatic diseases may sometimes become apparent after trauma, be associated with certain diseases and may be induced by nerve damage and serum sickness. Systemic lupuserythemat...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197510050-00008

    authors: Smyth CJ,Bravo JF

    更新日期:1975-01-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

    abstract:BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0382-1

    authors: Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

    更新日期:2015-04-01 00:00:00

  • Liposomal drug formulations. Rationale for development and what we can expect for the future.

    abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00001

    authors: Allen TM

    更新日期:1998-11-01 00:00:00

  • Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

    abstract::Varicella zoster virus (VZV), a member of the herpesvirus family, is responsible for both primary (varicella, chickenpox) as well as reactivation (zoster, shingles) infections. In immunocompetent patients, the course of varicella is generally benign. For varicella zoster, post-herpetic neuralgia is the most common com...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957020-00005

    authors: Snoeck R,Andrei G,De Clercq E

    更新日期:1999-02-01 00:00:00

  • The use of quinolones in developing countries.

    abstract::The size of the antibiotic market in developing countries is double that seen in developed countries. There are some valid reasons for this difference, one of which is the higher frequency of diverse infections in the developing world. However, other factors are involved: for example, antibiotics are available without...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300453-00009

    authors: Rodríguez-Noriega E,Morfin-Otero R,Esparza-Ahumada S

    更新日期:1993-01-01 00:00:00

  • A comparison of nimesulide vs paracetamol in the treatment of pyrexia in the elderly.

    abstract::The efficacy and safety of rectally administered nimesulide 200mg and paracetamol 500mg were assessed in a double-blind study. The study was conducted in 39 elderly inpatients with infections of the upper or lower respiratory tract associated with fever; 18 patients received nimesulide and 21 received paracetamol. Bot...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300461-00026

    authors: Cunietti E,Monti M,Viganò A,D'Aprile E,Saligari A,Scafuro E,Scaricabarozzi I

    更新日期:1993-01-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.

    abstract::Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11635960-000000000-00000

    authors: Ryan J,Ancelin ML

    更新日期:2012-09-10 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

    abstract::Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic ac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11640880-000000000-00000

    authors: Angiolillo DJ

    更新日期:2012-11-12 00:00:00

  • Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

    abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448040-00006

    authors: Northfelt DW

    更新日期:1994-10-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

    abstract::During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris. Although much data have accumulated, its precise mechanisms of action in these diseases remain largely uncertain. Optimum treatment of...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198631050-00002

    authors: Benfield P,Clissold SP,Brogden RN

    更新日期:1986-05-01 00:00:00

  • Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0666-0

    authors: Garnock-Jones KP

    更新日期:2017-01-01 00:00:00

  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

    abstract::Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly imp...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363210-00001

    authors: Bradford DW,Perkins DO,Lieberman JA

    更新日期:2003-01-01 00:00:00

  • Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

    abstract::Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0421-y

    authors: Keating GM

    更新日期:2015-07-01 00:00:00

  • Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

    abstract::Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole. Duodenal ulcers healed faster after treatment with rabeprazole 20 or 40 mg/day than placebo or ranitidine 150 mg 4 times daily and at a generally similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958040-00014

    authors: Langtry HD,Markham A

    更新日期:1999-10-01 00:00:00

  • Macitentan: a review of its use in patients with pulmonary arterial hypertension.

    abstract::Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0266-9

    authors: Dhillon S

    更新日期:2014-09-01 00:00:00

  • Cenegermin: A Review in Neurotrophic Keratitis.

    abstract::Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01289-w

    authors: Deeks ED,Lamb YN

    更新日期:2020-04-01 00:00:00

  • Dofetilide: a review of its use in atrial fibrillation and atrial flutter.

    abstract:UNLABELLED:Dofetilide is a 'pure' class III antiarrhythmic agent which has demonstrated efficacy in the conversion of atrial fibrillation or flutter to sinus rhythm and the maintenance of sinus rhythm. By blocking the rapid component of the cardiac delayed rectifier potassium current (I(Kr)), dofetilide prolongs the ca...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958060-00007

    authors: McClellan KJ,Markham A

    更新日期:1999-12-01 00:00:00